MLAB - Mesa Laboratories Inc Stock Price, Fair Value and News

119.87USD-0.74 (-0.61%)Delayed as of 17 May 2024, 11:36 am ET

Market Summary

USD119.87-0.74

Delayedas of 17 May 2024, 11:36 am

-0.61%

MLAB Stock Price

View Fullscreen

MLAB RSI Chart

MLAB Valuation

Market Cap

650.6M

Price/Earnings (Trailing)

686.26

Price/Sales (Trailing)

3.06

EV/EBITDA

20.81

Price/Free Cashflow

15.98

MLAB Price/Sales (Trailing)

MLAB Profitability

Operating Margin

61.02%

EBT Margin

-0.28%

Return on Equity

0.24%

Return on Assets

0.13%

Free Cashflow Yield

6.26%

MLAB Fundamentals

MLAB Revenue

Revenue (TTM)

212.9M

Rev. Growth (Yr)

-1.5%

Rev. Growth (Qtr)

0.58%

MLAB Earnings

Earnings (TTM)

948.0K

Earnings Growth (Yr)

369.18%

Earnings Growth (Qtr)

272.03%

Breaking Down MLAB Revenue

52 Week Range

96.05162.83

(Low)(High)

Last 7 days

2.3%

Last 30 days

16.9%

Last 90 days

16.7%

Trailing 12 Months

-23.5%

How does MLAB drawdown profile look like?

MLAB Financial Health

Current Ratio

2.68

Debt/Equity

0.42

Debt/Cashflow

0.26

MLAB Investor Care

Dividend Yield

0.53%

Dividend/Share (TTM)

0.64

Shares Dilution (1Y)

0.90%

Diluted EPS (TTM)

0.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	219.1M	219.3M	213.7M	212.9M
2022	184.3M	199.9M	222.8M	222.4M
2021	133.9M	138.9M	142.9M	163.4M
2020	117.7M	121.3M	127.7M	130.2M
2019	103.1M	104.3M	105.0M	109.9M
2018	96.2M	98.6M	100.6M	103.6M
2017	93.7M	95.2M	93.8M	93.6M
2016	84.7M	87.6M	90.2M	94.2M
2015	71.3M	73.1M	76.3M	78.4M
2014	52.7M	57.9M	63.8M	68.5M
2013	46.4M	47.1M	48.1M	49.8M
2012	39.6M	40.9M	42.9M	44.6M
2011	34.2M	35.7M	37.4M	39.0M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Mesa Laboratories Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 15, 2023	archbold brian david	sold	-168,540	112	-1,500	svp operations
Nov 09, 2023	sullivan john james	gifted	-	-	200	-
Nov 09, 2023	sullivan john james	gifted	-	-	-2,200	-
Sep 15, 2023	schmieder john bradley	sold	-123,740	123	-1,000	-
Sep 14, 2023	schmieder john bradley	sold	-369,150	123	-3,000	-
Sep 13, 2023	schmieder john bradley	sold	-369,965	123	-3,000	-
Sep 01, 2023	owens gary m	sold	-285,640	142	-2,000	president and ceo
Sep 01, 2023	owens gary m	acquired	272,840	136	2,000	president and ceo
Aug 15, 2023	hall shannon	acquired	-	-	754	-
Aug 15, 2023	ladiwala shiraz shabanali	acquired	-	-	40.00	-

Which funds bought or sold MLAB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	B. Riley Asset Management, LLC	sold off	-100	-1,187,570	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-91.25	-115,245	11,631	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	206,292	206,292	-%
May 15, 2024	MARSHALL WACE, LLP	added	66.68	1,238,010	2,898,300	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	3,841	3,841	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-87.94	-6,052,080	875,208	-%
May 15, 2024	ZACKS INVESTMENT MANAGEMENT	added	43.65	855,426	2,551,130	0.03%
May 15, 2024	JANUS HENDERSON GROUP PLC	reduced	-0.04	10,259	252,515	-%
May 15, 2024	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	reduced	-10.79	-130,050	1,851,260	0.01%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	sold off	-100	-451,873	-	-%

Are Funds Buying or Selling MLAB?

Are funds buying MLAB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MLAB

No. of Funds

Unveiling Mesa Laboratories Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	6.87%	370,278	SC 13G/A
Jan 23, 2024	royce & associates lp	5.%	269,645	SC 13G/A
Jan 22, 2024	blackrock inc.	15.7%	845,773	SC 13G/A
Jan 05, 2024	conestoga capital advisors, llc	11.45%	617,612	SC 13G/A
Feb 09, 2023	vanguard group inc	6.73%	359,293	SC 13G/A
Feb 02, 2023	invesco ltd.	4.4%	232,427	SC 13G/A
Jan 27, 2023	royce & associates lp	3.01%	160,577	SC 13G/A
Jan 26, 2023	blackrock inc.	16.4%	874,324	SC 13G/A
Jan 20, 2023	blackrock inc.	16.4%	874,324	SC 13G/A
Jan 18, 2023	conestoga capital advisors, llc	11.34%	605,117	SC 13G/A

Recent SEC filings of Mesa Laboratories Inc

View All Filings

Date Filed	Form Type	Document
Apr 08, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	8-K	Current Report
Apr 02, 2024	UPLOAD	UPLOAD
Mar 26, 2024	4	Insider Trading
Mar 25, 2024	CORRESP	CORRESP
Mar 20, 2024	UPLOAD	UPLOAD

Peers (Alternatives to Mesa Laboratories Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AAPL	2.9T	381.6B	12.11%	9.97%	29.01	7.63	-0.90%	6.43%
APH	79.1B	12.8B	16.99%	74.51%	38.82	6.16	1.52%	6.35%
GLW	30.2B	12.4B	13.87%	14.24%	48.84	2.44	-9.51%	-33.28%
FTV	27.2B	6.1B	-4.63%	18.71%	30.24	4.44	3.71%	17.79%
FLEX	12.3B	29.4B	3.40%	21.80%	16.31	0.42	-1.12%	-8.06%
MID-CAP
CGNX	8.2B	847.2M	19.89%	-8.53%	81.83	9.62	-8.39%	-42.67%
ARW	6.9B	31.3B	5.10%	6.55%	9.69	0.22	-14.93%	-46.67%
BMI	5.8B	740.8M	27.40%	41.30%	56.26	7.77	25.07%	42.99%
AVT	4.8B	24.7B	12.59%	26.71%	8.4	0.19	-6.09%	-33.76%
ESE	2.8B	988.8M	9.38%	11.83%	28.33	2.82	8.64%	13.26%
SMALL-CAP
CNXN	1.8B	2.8B	8.75%	56.18%	21.73	0.65	-10.09%	0.74%
BHE	1.5B	2.8B	36.23%	86.97%	22.28	0.52	-4.25%	-5.27%
GPRO	249.3M	986.2M	-6.78%	-58.75%	-0.69	0.25	-6.21%	-5303.34%
CPSH	25.3M	26.4M	4.07%	-40.13%	32.9	0.96	-2.48%	-64.63%
AEY	23.3M	56.7M	-33.90%	1.30%	-3.8	0.59	-41.04%	-726.48%

Mesa Laboratories Inc News

Latest updates

Mesa Laboratories Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	0.6%	53.00	53.00	51.00	56.00	54.00	59.00	50.00	59.00	55.00	36.00	35.00	38.00	34.00	32.00	30.00	34.00	32.00	26.00	26.00	26.00	27.00
Cost Of Revenue	-4.7%	20.00	21.00	19.00	22.00	22.00	22.00	19.00	24.00	26.00	13.00	13.00	13.00	14.00	11.00	10.00	15.00	17.00	10.00	10.00	11.00	11.00
Gross Profit	4.0%	33.00	32.00	31.00	33.00	33.00	36.00	31.00	35.00	29.00	23.00	22.00	25.00	21.00	21.00	20.00	19.00	15.00	16.00	16.00	16.00	16.00
Operating Expenses	4.0%	33.00	32.00	32.00	33.00	29.00	32.00	36.00	35.00	31.00	19.00	19.00	20.00	21.00	17.00	17.00	18.00	18.00	11.00	11.00	13.00	14.00
S&GA Expenses	0.9%	10.00	10.00	9.00	10.00	8.00	9.00	10.00	10.00	9.00	5.00	5.00	6.00	5.00	4.00	4.00	4.00	4.00	2.00	2.00	3.00	2.00
R&D Expenses	-14.0%	4.00	5.00	5.00	5.00	5.00	5.00	6.00	5.00	5.00	3.00	3.00	3.00	3.00	2.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00
EBITDA Margin	1.4%	0.18*	0.18*	0.19*	0.17*	0.24*	0.21*	0.22*	0.26*	0.25*	0.25*	0.25*	0.26*	-	-	-	-	-	-	-	-	-
Interest Expenses	105.1%	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	0.00	0.00	0.00
Income Taxes	-78.9%	-0.17	-0.09	-0.39	-0.89	1.00	2.00	-3.97	2.00	-0.28	1.00	-0.58	1.00	-1.18	-0.29	-0.46	1.00	-0.57	1.00	1.00	1.00	0.00
Earnings Before Taxes	246.9%	2.00	-1.32	-0.94	-0.28	2.00	3.00	-5.41	-0.05	-2.34	5.00	1.00	5.00	-5.73	2.00	1.00	-0.23	-5.08	4.00	5.00	2.00	1.00
EBT Margin	4.4%	0.00*	0.00*	0.02*	0.00*	0.00*	-0.02*	-0.02*	0.02*	0.05*	0.04*	0.02*	0.02*	-	-	-	-	-	-	-	-	-
Net Income	272.0%	2.00	-1.23	-0.55	1.00	0.00	1.00	-1.44	-1.78	-2.06	4.00	2.00	4.00	-4.54	3.00	1.00	-1.55	-4.50	3.00	5.00	1.00	1.00
Net Income Margin	232.7%	0.00*	0.00*	0.01*	0.00*	-0.01*	-0.02*	-0.01*	0.01*	0.05*	0.04*	0.03*	0.02*	-	-	-	-	-	-	-	-	-
Free Cashflow	13.8%	10.00	9.00	10.00	11.00	6.00	9.00	-3.04	9.00	14.00	3.00	9.00	12.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	16.4%	742	637	643	662	663	656	686	707	722	609	612	601	622	589	577	409	423	392	160	157	158
Current Assets	0.6%	118	118	115	119	114	116	128	124	121	319	315	304	295	280	270	123	121	271	34.00	34.00	33.00
Cash Equivalents	-20.8%	28.00	36.00	32.00	33.00	26.00	32.00	44.00	49.00	52.00	278	276	264	254	242	231	81.00	74.00	245	7.00	10.00	6.00
Inventory	9.4%	36.00	33.00	36.00	35.00	34.00	28.00	27.00	25.00	24.00	12.00	25.00	11.00	12.00	12.00	13.00	11.00	19.00	7.00	7.00	7.00	8.00
Net PPE	11.2%	32.00	29.00	28.00	28.00	28.00	28.00	28.00	29.00	30.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	22.00	23.00
Goodwill	22.2%	346	283	284	286	286	278	284	291	294	160	163	161	166	156	154	142	190	67.00	67.00	66.00	-
Liabilities	35.8%	339	249	255	268	276	282	305	314	325	210	213	195	209	197	194	189	189	163	41.00	45.00	51.00
Current Liabilities	11.0%	44.00	40.00	39.00	43.00	42.00	42.00	44.00	48.00	47.00	29.00	33.00	33.00	28.00	20.00	20.00	26.00	25.00	17.00	21.00	24.00	21.00
Long Term Debt	0.1%	171	171	171	170	170	170	170	169	169	169	169	146	144	143	142	140	139	138	18.00	21.00	27.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	2.00
LT Debt, Non Current	0.1%	171	171	171	170	170	170	170	169	169	169	169	146	144	143	142	140	139	138	18.00	21.00	27.00
Shareholder's Equity	3.9%	403	388	388	393	387	374	380	394	396	399	399	406	413	392	382	220	235	230	119	111	108
Retained Earnings	1.8%	72.00	71.00	73.00	74.00	74.00	75.00	74.00	77.00	79.00	82.00	79.00	72.00	69.00	75.00	72.00	72.00	74.00	80.00	77.00	73.00	73.00
Accumulated Depreciation	5.9%	23.00	21.00	20.00	20.00	20.00	19.00	18.00	18.00	18.00	-	-	16.00	15.00	14.00	13.00	13.00	15.00	-	-	11.00	-
Shares Outstanding	0.0%	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	713	-	-	-	1,454	-	-	-	1,221	-	-	-	973	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	18.0%	11,535	9,776	9,939	12,519	7,718	10,557	-2,811	9,302	15,898	4,434	9,589	13,520	10,943	10,350	2,260	8,832	11,007	6,425	724	10,262	10,092
Share Based Compensation	-6.0%	2,993	3,183	2,968	2,679	2,056	4,371	3,432	3,452	3,703	2,039	2,197	2,381	3,611	2,008	1,268	215	3,260	1,182	868	1,788	695
Cashflow From Investing	-12648.9%	-80,828	-634	-270	-1,026	-6,604	-1,639	-225	-782	-302,852	-938	-653	-1,038	-247	-491	-216	-548	-181,939	-317	-2,781	-55.00	-5,198
Cashflow From Financing	1194.4%	60,848	-5,560	-9,519	-4,392	-8,883	-18,646	-1,407	-10,047	61,200	1,158	265	-1,047	171	219	146,885	394	-357	232,155	-915	-5,615	-4,757
Dividend Payments	0%	862	862	859	856	855	852	843	844	837	834	824	824	819	818	704	703	698	697	624	619	617

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MLAB Income Statement

2023-12-31

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 53,473	$ 54,287	$ 157,283	$ 163,489
Cost of revenues	20,071	21,522	60,589	62,997
Gross profit	33,402	32,765	96,694	100,492
Operating expense:
Selling	9,737	8,437	28,363	27,660
General and administrative	19,438	16,129	55,024	54,543
Research and development	4,294	4,797	14,098	15,486
Total operating expense	33,469	29,363	97,485	97,689
Operating (loss) income	(67)	3,402	(791)	2,803
Nonoperating expense:
Interest expense and amortization of debt issuance costs	1,856	1,162	3,809	3,390
Other (income) expense, net	(3,869)	324	(4,284)	(475)
Total nonoperating (income) expense, net	(2,013)	1,486	(475)	2,915
Earnings (loss) before income taxes	1,946	1,916	(316)	(112)
Income tax (benefit) expense	(170)	1,465	(653)	(431)
Net (loss) income	$ 2,116	$ 451	$ 337	$ 319
Earnings per share:
Basic earnings per share (in dollars per share)	$ 0.39	$ 0.08	$ 0.06	$ 0.06
Diluted earnings per share (in dollars per share)	$ 0.39	$ 0.08	$ 0.06	$ 0.06
Weighted-average common shares outstanding:
Basic (in shares)	5,393	5,339	5,384	5,312
Fully diluted shares (in shares)	5,396	5,360	5,394	5,354

MLAB Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Cash and cash equivalents	$ 28,224	$ 32,910
Accounts receivable, less allowance for doubtful accounts of $1,363 and $849, respectively	36,023	42,551
Inventories	35,973	34,642
Prepaid expenses and other	18,135	8,872
Total current assets	118,355	118,975
Noncurrent assets:
Property, plant and equipment, net of accumulated depreciation of $22,574 and $19,768 respectively	31,775	28,149
Deferred tax asset	1,092	1,076
Other assets	11,590	10,373
Intangible assets	232,774	216,815
Goodwill	346,183	286,444
Total assets	741,769	661,832
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	4,554	6,134
Accrued payroll and benefits	9,380	9,433
Unearned revenues	14,357	15,694
Other accrued expenses	15,892	12,098
Total current liabilities	44,183	43,359
Noncurrent liabilities:
Deferred tax liability	44,340	34,028
Other long-term liabilities	17,320	7,693
Credit facility	62,000	13,000
Convertible senior notes, net of debt issuance costs	170,965	170,272
Total liabilities	338,808	268,352
Stockholders’ equity:
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,394,043 and 5,369,466 shares, respectively	340,852	332,076
Retained earnings	71,953	74,199
Accumulated other comprehensive (loss)	(9,844)	(12,795)
Total stockholders’ equity	402,961	393,480
Total liabilities and stockholders’ equity	741,769	661,832
Customer Relationships [Member]
Noncurrent assets:
Intangible assets	162,890	152,189
Intellectual Property [Member]
Noncurrent assets:
Intangible assets	45,753	46,400
Other Intangible Assets [Member]
Noncurrent assets:
Intangible assets	$ 24,131	$ 18,226

About Mesa Laboratories Inc

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

CEO	Mr. Gary M. Owens
WEBSITE	mesalabs.com
INDUSTRY	Consumer Electronics
EMPLOYEES	698

Mesa Laboratories Inc Frequently Asked Questions

What is the ticker symbol for Mesa Laboratories Inc? What does MLAB stand for in stocks?

MLAB is the stock ticker symbol of Mesa Laboratories Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mesa Laboratories Inc (MLAB)?

As of Thu May 16 2024, market cap of Mesa Laboratories Inc is 650.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MLAB stock?

You can check MLAB's fair value in chart for subscribers.

What is the fair value of MLAB stock?

You can check MLAB's fair value in chart for subscribers. The fair value of Mesa Laboratories Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mesa Laboratories Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MLAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mesa Laboratories Inc a good stock to buy?

The fair value guage provides a quick view whether MLAB is over valued or under valued. Whether Mesa Laboratories Inc is cheap or expensive depends on the assumptions which impact Mesa Laboratories Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MLAB.

What is Mesa Laboratories Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, MLAB's PE ratio (Price to Earnings) is 686.26 and Price to Sales (PS) ratio is 3.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MLAB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Mesa Laboratories Inc's stock?

In the past 10 years, Mesa Laboratories Inc has provided 0.049 (multiply by 100 for percentage) rate of return.